FIELD: medicine; pharmaceutics.
SUBSTANCE: first invention is the use of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidine-1-yl)pyrrolidine-1-yl)prop-2-en-1-one or its pharmaceutically acceptable salt for the treatment of a patient with cancer, receiving one or more additional compounds with an antitumor effect or their pharmaceutically acceptable salt(s), selected from 5-fluoruracil, tegafur/himeracil/potassium oteracil, gemcitabine, paclitaxel, cisplatin, everolimus, MK2206, and trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazine-2-yl)phenyl)cyclobutanol, gefitinib. The second invention is a method for the treatment of tumor, including the administration of the specified combinations to a patient who needs it.
EFFECT: group of inventions provides for a synergetic effect of antitumor combinations.
26 cl, 32 dwg, 4 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING AND PREVENTING TUMOUR WHICH IS AMENABLE TO ENDOCRINE THERAPY, USING COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND ENDOCRINE THERAPY | 2019 |
|
RU2825636C2 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
| CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2016 |
|
RU2729636C2 |
| NEW PHOSPHATE ETHER COMPOUND HAVING A PYRROLOPYRIMIDINE SKELETON, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2020 |
|
RU2801306C2 |
| ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | 2014 |
|
RU2664118C2 |
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| NEW CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2017 |
|
RU2770727C2 |
| METHOD OF TREATING MALIGNANT TUMOUR | 2020 |
|
RU2816126C2 |
| DERIVATIVE OF 3Т-ETHYNILCYTIDINE | 2007 |
|
RU2441876C2 |
